Breakthrough Status recognizes SonoCloud system as innovative and promising approach for treatment of recurrent glioblastoma
Paris, France, June 22, 2022 – Carthera, a French company that designs and develops SonoCloud, an innovative ultrasound-based medical device to treat a wide range of brain diseases, announces today that its SonoCloud-9 ® system has been listed as a Breakthrough Device by the Center for Devices and Radiological Health (CDRH) at the US Food and Drug Administration (FDA).
The SonoCloud device uses low intensity pulsed ultrasound to temporarily disrupt the Blood-Brain Barrier (BBB), to allow higher brain exposure to therapeutic compounds. By using SonoCloud, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases, such as glioblastoma.